By Editorial Team
CrystalysReported
Crystalys mines $130M series B to push gout drug through phase 3.
The round
Biotech firm Crystalys has successfully closed a Series B funding round, securing $130 million. The company announced the new capital infusion, which is earmarked for advancing its lead therapeutic candidate. The specific lead investor and other participating investors in this Series B round were not disclosed.
What Crystalys does
Crystalys operates within the biotech sector, focusing on the development of pharmaceutical treatments. Their primary current endeavor centers on a drug designed to address gout, a painful form of inflammatory arthritis.
What the funding will do
The $130 million raised in the Series B round is specifically allocated to propel Crystalys’s gout drug through its critical Phase 3 clinical trials. This stage of development is a significant step towards potential regulatory approval and subsequent market availability.
Why it matters
This substantial Series B funding for Crystalys highlights continued investor interest in the biotech space, particularly for companies developing treatments for chronic conditions like gout. Successfully navigating Phase 3 trials is a major milestone for any pharmaceutical company, often requiring considerable financial resources. The investment in Crystalys underscores the potential perceived in their gout drug candidate and its ability to address an unmet medical need within the rheumatology field.